AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39083052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy pilates-assisted birth preparation training (twice a week for 8 weeks)
Number of subjects: 126
Study 39083052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy pilates-assisted birth preparation training
Number of subjects: 126
Study 39083105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of radiolabeled antibody
Number of subjects: 0
Study 39083099 — intervention group
Group type: EXPERIMENTAL
Intervention: VACStent treatment for anastomotic leak (AL) without stoma placement
Number of subjects: 12
Study 39083099 — intervention group
Group type: EXPERIMENTAL
Intervention: VACStent treatment for anastomotic leak (AL) after stoma placement
Number of subjects: 12
Study 39083099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic VACStent applications for high-risk anastomoses
Number of subjects: 12
Study 39083147 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 60
Study 39083147 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab treat-and-extend (T&E)
Number of subjects: 60
Study 39083147 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 60
Study 39083147 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab (both Q8W and T&E)
Number of subjects: 60
Study 39083147 — intervention group
Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 60
Study 39083185 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter implants with immediate provisionalization
Number of subjects: 77
Study 39083200 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 30
Study 39083200 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study 39083288 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 16 weeks
Number of subjects: 822
Study 39083288 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 822
Study 39083323 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted PET/CT imaging before anti-HER2 therapy
Number of subjects: 59
Study 39083323 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted PET/CT imaging
Number of subjects: 59
Study 39083331 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message reminder on the 14th day of kit pick up
Number of subjects: 9369
Study 39083331 — intervention group
Group type: COMPARATOR
Intervention: No reminder (control group)
Number of subjects: 9369
Study 39083331 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message reminder
Number of subjects: 9369
Study 39083340 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach-led, asynchronous, text-based digital behavior change coaching intervention (DBCCI)
Number of subjects: 107
Study 39083478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal synchrony intervention
Number of subjects: 0
Study 39083478 — intervention group
Group type: COMPARATOR
Intervention: Group non-synchronous intervention
Number of subjects: 0
Study 39083494 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking aid group (A)
Number of subjects: 0
Study 39083494 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking aid and telemonitoring group (B)
Number of subjects: 0
Study 39083494 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 39083526 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) for 2 weeks
Number of subjects: 75
Study 39083526 — intervention group
Group type: COMPARATOR
Intervention: Sham group (noneffective stimulation)
Number of subjects: 75
Study 39083526 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) for healthy controls
Number of subjects: 75
Study 39083587 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine
Number of subjects: 0
Study 39083587 — intervention group
Group type: COMPARATOR
Intervention: Alum-adjuvanted vaccine
Number of subjects: 0
Study 39083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg once on days 1 and 8 every 3 weeks
Number of subjects: 41
Study 39083792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) administered via a web-based application, 1-hour sessions weekly for 4 weeks
Number of subjects: 20
Study 39083792 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with home exercises provided on paper, 1-hour sessions weekly for 4 weeks
Number of subjects: 20
Study 39083792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic+TR group with in-person sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Number of subjects: 20
Study 39083792 — intervention group
Group type: EXPERIMENTAL
Intervention: TR-only group with virtual sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Number of subjects: 20
Study 39083801 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) data with 5%-50% data loss
Number of subjects: 84
Study 39083801 — intervention group
Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM) data without data loss
Number of subjects: 84
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as stimulated C-peptide >300 pmol/l
Number of subjects: 133
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose-adjusted HbA1c ≤9%
Number of subjects: 133
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose <0.3 IU/kg/24 h and HbA1c ≤6.4% (46 mmol/mol)
Number of subjects: 133
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose <0.5 IU/kg/24 h and HbA1c <7% (53 mmol/mol)
Number of subjects: 133
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of age, HbA1c, diastolic blood pressure, triglycerides and smoking at T1D onset
Number of subjects: 133
Study 39084177 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c, triglycerides and insulin dose 3-months post-diagnosis
Number of subjects: 133
Study 39084489 — intervention group
Group type: EXPERIMENTAL
Intervention: KT-474, a targeted degrader of IRAK4, ex vivo treatment of PBMCs from healthy volunteers and patients with HS.
Number of subjects: 30
Study 39084489 — intervention group
Group type: EXPERIMENTAL
Intervention: KT-474, ex vivo treatment of toll-like receptor-stimulated healthy donor monocytes.
Number of subjects: 30
Study 39084489 — intervention group
Group type: COMPARATOR
Intervention: HS lesional skin samples compared to nonlesional tissue.
Number of subjects: 30
Study 39084489 — intervention group
Group type: EXPERIMENTAL
Intervention: HS lesional skin samples.
Number of subjects: 30
Study 39084517 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-adapted and personally tailored decision aid
Number of subjects: 40
Study 39084707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study 39084707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39084827 — intervention group
Group type: EXPERIMENTAL
Intervention: Jewel patch-wearable cardioverter-defibrillator (P-WCD)
Number of subjects: 305
Study 39084829 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41
Study 39084829 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 41
Study 39084863 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy mutation carriers (HMC) with elevated t-tau (>290 pg/mL)
Number of subjects: 60
Study 39084863 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic gCJD patients
Number of subjects: 60
Study 39084863 — intervention group
Group type: COMPARATOR
Intervention: Healthy relatives (non-carriers)
Number of subjects: 60
Study 39084935 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm for predicting PD-L1 expression and immunotherapy prognosis
Number of subjects: 204
Study 39084935 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model predicting treatment response in PD-L1 high-expression patients
Number of subjects: 204
Study 39084935 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model predicting improved survival in PD-L1 high-expression patients
Number of subjects: 204
Study 39085080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily for up to 6 or 8 weeks
Number of subjects: 0
Study 39085080 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily for up to 6 or 8 weeks
Number of subjects: 0
Study 39085080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan in patients aged <65 years
Number of subjects: 0
Study 39085080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan in current smokers
Number of subjects: 0
Study 39085080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan in the Chinese subpopulation
Number of subjects: 0
Study 39085080 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole in the Chinese subpopulation
Number of subjects: 0
Study 39085080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Number of subjects: 0
Study 39085080 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 0
Study 39085322 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical solution of plant terpenes containing camphor, menthol, eugenol, eucalyptol, and vanillin with 15% DMSO, 1% limonene, and rosemary oil applied topically twice daily.
Number of subjects: 62
Study 39085322 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study 39085438 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding training with virtual reality (VR) at 4th and 24th hours after cesarean delivery
Number of subjects: 66
Study 39085438 — intervention group
Group type: COMPARATOR
Intervention: Standard breastfeeding training
Number of subjects: 66
Study 39085487 — intervention group
Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 1
Study 39085487 — intervention group
Group type: EXPERIMENTAL
Intervention: wearable technology
Number of subjects: 1
Study 39085664 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (AUR)
Number of subjects: 115
Study 39085664 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 115
Study 39085664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Auriculotherapy and Acupuncture (AUR-ACU)
Number of subjects: 115
Study 39085664 — intervention group
Group type: COMPARATOR
Intervention: Usual Treatment (UT)
Number of subjects: 115
Study 39085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Awareness Scale (OAS)
Number of subjects: 325
Study 39085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Osteoporosis Knowledge Test (R-OKT)
Number of subjects: 325
Study 39085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall risk assessment using timed up-and-go test
Number of subjects: 325
Study 39085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OAS scores and fall risk
Number of subjects: 325
Study 39085782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 160
Study 39085831 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP (6 weekly sessions)
Number of subjects: 34
Study 39085831 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP + HBCC (6 weekly sessions)
Number of subjects: 34
Study 39085831 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study 39085889 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of cancer (FHC)
Number of subjects: 53
Study 39085889 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of lung cancer
Number of subjects: 53
Study 39085889 — intervention group
Group type: COMPARATOR
Intervention: Germline mutations (ATM, BRCA2, TP53)
Number of subjects: 53
Study 39085889 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHIC-Lung study
Number of subjects: 53
Study 39085927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle interventions (MLI) - 3 months of weekly 2-hour sessions on diet education, yoga, music therapy, and cognitive skills training.
Number of subjects: 200
Study 39085927 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 200
Study 39085927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle interventions (MLI)
Number of subjects: 200
Study 39085940 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies employed by first-line managers
Number of subjects: 30
Study 39085940 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to guideline implementation
Number of subjects: 30
Study 39085940 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational support for CPG implementation
Number of subjects: 30
Study 39085951 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS with active TaVNS (25 Hz, 200 µs)
Number of subjects: 30
Study 39085951 — intervention group
Group type: COMPARATOR
Intervention: TENS with placebo TaVNS
Number of subjects: 30
Study 39085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict BP control (SBP < 130 mmHg)
Number of subjects: 341
Study 39085979 — intervention group
Group type: COMPARATOR
Intervention: Standard BP control (SBP < 140 mmHg)
Number of subjects: 341
Study 39085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved average SBP of 130-139 mmHg
Number of subjects: 341
Study 39085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved average SBP < 130 mmHg
Number of subjects: 341
Study 39086130 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 622
Study 39086144 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Packer Managing Fatigue program
Number of subjects: 0
Study 39086163 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Rhythm for Mood (CRM) digital therapeutic
Number of subjects: 0
Study 39086163 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 39086310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 192
Study 39086673 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-mediated gene augmentation therapy for GSD-Ia (NCT05139316)
Number of subjects: 0
Study 39086673 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA augmentation for GSD-Ia (NCT05095727)
Number of subjects: 0
Study 39086673 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative genetic technologies for GSD-I therapies (gene editing)
Number of subjects: 0
Study 39086728 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep H-coil rTMS targeting the primary motor cortex
Number of subjects: 17
Study 39086728 — intervention group
Group type: COMPARATOR
Intervention: Sham deep H-coil rTMS targeting the primary motor cortex
Number of subjects: 17
Study 39086857 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional fitness training and mastering physical literacy class twice a week with buddy peer support for 12 weeks, including reflective writing journal.
Number of subjects: 10
Study 39086857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 10
Study 39086948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 126
Study 39086948 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 39086991 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP-lowering diet supported by a smartphone application for 8 weeks
Number of subjects: 222
Study 39086991 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP-lowering diet supported by a smartphone application
Number of subjects: 222
Study 39087204 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster families
Number of subjects: 107
Study 39087204 — intervention group
Group type: COMPARATOR
Intervention: Nursing homes
Number of subjects: 107
Study 39087355 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 200
Study 39087355 — intervention group
Group type: COMPARATOR
Intervention: Control (no valsartan treatment)
Number of subjects: 200
Study 39087355 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical HCM
Number of subjects: 200
Study 39087355 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage HCM
Number of subjects: 200
Study 39087564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 659
Study 39087734 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent trauma-focused and personality disorder treatment
Number of subjects: 0
Study 39087734 — intervention group
Group type: COMPARATOR
Intervention: Only trauma-focused treatment
Number of subjects: 0
Study 39087741 — intervention group
Group type: EXPERIMENTAL
Intervention: Perclose ProGlide (PPG) Suture-Mediated Closure System
Number of subjects: 100
Study 39087741 — intervention group
Group type: COMPARATOR
Intervention: figure of 8 suture
Number of subjects: 100
Study 39087785 — intervention group
Group type: EXPERIMENTAL
Intervention: sRBC transfusion
Number of subjects: 174
Study 39087785 — intervention group
Group type: COMPARATOR
Intervention: Baseline samples
Number of subjects: 174
Study 39087785 — intervention group
Group type: COMPARATOR
Intervention: pRBCs
Number of subjects: 174
Study 39087868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg three times daily before meals (BM-TID)
Number of subjects: 327
Study 39087868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg three times daily after meals (AM-TID)
Number of subjects: 327
Study 39087868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg four times daily after meals (AM-QID)
Number of subjects: 327
Study 39088062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital heparin administration
Number of subjects: 394
Study 39088062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-hospital heparin)
Number of subjects: 394
Study 39088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged awake prone positioning (target > 12 h daily for 7 days)
Number of subjects: 409
Study 39088076 — intervention group
Group type: COMPARATOR
Intervention: Standard care (shorter period of awake prone positioning)
Number of subjects: 409
Study 39088076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged awake prone positioning
Number of subjects: 409
Study 39088076 — intervention group
Group type: COMPARATOR
Intervention: Prolonged awake prone positioning and Standard care
Number of subjects: 409
Study 39088196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar resection
Number of subjects: 697
Study 39088196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 697
Study 39088196 — intervention group
Group type: COMPARATOR
Intervention: Patients with pT1 tumors
Number of subjects: 697
Study 39088196 — intervention group
Group type: COMPARATOR
Intervention: Patients with pT2 tumors
Number of subjects: 697
Study 39088200 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled ultrasonography tool (index test)
Number of subjects: 400
Study 39088200 — intervention group
Group type: COMPARATOR
Intervention: Standard biometry by credentialed sonographers (study standard)
Number of subjects: 400
Study 39088212 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA)
Number of subjects: 102
Study 39088212 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA) among APOE*E4 carriers
Number of subjects: 102
Study 39088212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 102
Study 39088215 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based multifactorial intervention screening (noninterruptive EHR alert combined with confidential screening by computer questionnaire)
Number of subjects: 8895
Study 39088215 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential screening process
Number of subjects: 8895
Study 39088218 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 208
Study 39088218 — intervention group
Group type: COMPARATOR
Intervention: Control 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 208
Study 39088254 — intervention group
Group type: EXPERIMENTAL
Intervention: OKquit smartphone app for smoking cessation
Number of subjects: 500
Study 39088254 — intervention group
Group type: COMPARATOR
Intervention: Standard OTH care (SC)
Number of subjects: 500
Study 39088271 — intervention group
Group type: EXPERIMENTAL
Intervention: CE+p55Gag
Number of subjects: 56
Study 39088271 — intervention group
Group type: COMPARATOR
Intervention: p55Gag
Number of subjects: 56
Study 39088271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 56
Study 39088339 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 130
Study 39088370 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beats intervention, details on dosage and duration not available
Number of subjects: 0
Study 39088370 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 39088398 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen deprivation therapy (ADT); 240 mg daily for 12 cycles (28-day cycles)
Number of subjects: 108
Study 39088398 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT; 12 months after treatment completion
Number of subjects: 108
Study 39088398 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 108
Study 39088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report distress tool (DT)
Number of subjects: 400
Study 39088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid mental health referral process (MH)
Number of subjects: 400
Study 39088460 — intervention group
Group type: COMPARATOR
Intervention: Usual case management (C)
Number of subjects: 400
Study 39088470 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Choice (AC) intervention
Number of subjects: 743